Drugs / conventional IPV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03526978 Comparator | Aug → Oct 2017 | poliomyelitis | Sinovac Biotech Co., Ltd | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | conventional IPV | “The sIPV demonstrated an immunogenicity profile noninferior to that of the conventional IPV and had a good safety profile.” PMID 30958543 ↗ Oct 2019 |
| Known as | IPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03526978 ↗ |
| Modality | Vaccine | “The control vaccine is a commercialized Inactivated Poliovirus Vaccine” NCT03526978 ↗ |